INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma
One Biosciences Receives BOOST Funding From Paris-Saclay Cancer Cluster to Advance the First Single-Cell Assay Approach for ADC Therapies
Why Investors Need to Take Advantage of These 2 Finance Stocks Now
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Agree Realty: This Dividend Compounder Looks Attractive Again
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA – ADCT
Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and P
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Agree Realty And Global Net Lease: One Yields 4%, One Yields 8%. The Balance Sheet Sets The Spread.
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
Agree Realty Declares Monthly Common and Preferred Dividends
A Barbell Approach To Passive Income As Inflation Roars Back To Life
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
REITs May Crash Again- Here's Why, And Two REITs Income Investors Should Consider Buying
Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026
ADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6
Agree Realty Is Becoming More And More Attractive, But I'm Not Buying Yet
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
U.S. REIT At-The-Market Activity Dips In Q1 2026
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
Merck's ADC Candidate Meets Goals in Endometrial Cancer Study
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting
Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease
Agree Realty Declares Monthly Common and Preferred Dividends
Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program
ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
Agree Realty: Bigger Investments, Stronger Growth Amid Uncertainty Puts Them In A Different League
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
Agree Realty: Reliable Dividend Income To Weather The Macro Storm
Dividend Champion, Contender, And Challenger Highlights: Week Of April 26
This Portfolio Pays Me Every Month (No Work Needed)
These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your Radar
Agree Realty Corporation (ADC) Q1 2026 Earnings Call Transcript
Agree Realty (ADC) Surpasses Q1 FFO and Revenue Estimates